Vol 71, No 5 (2020)
Original paper
Published online: 2020-06-26

open access

Page views 2007
Article views/downloads 1523
Get Citation

Connect on Social Media

Connect on Social Media

Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and insulin resistance?

Erhan Onalan1, Cundullah Cavlı1, Yusuf Dogan1, Ebru Onalan2, Nevzat Gozel1, Ilay Buran2, Burkay Yakar3, Emir Donder1
Pubmed: 32598020
Endokrynol Pol 2020;71(5):397-403.

Abstract

Introduction: Meteorin-like (Metrnl), also known as subfatin, is a recently discovered adipokine with a favourable effect on insulin sensitivity. Studies have shown lower Metrnl levels in obese patients. However, data on its circulating levels in type 2 diabetes mellitus (T2DM) patients are contradictory. This study aims to evaluate serum Metrnl levels in T2DM patients and determine the relationship between serum Metrnl levels and insulin resistance in these patients.

Material and methods: This cross-sectional study was conducted among 150 participants. The study was carried out between June 2019 and December 2019 at the internal medicine outpatient clinic of a tertiary university hospital. The participants were divided into three groups: group 1 (control group, n = 50), group 2 (newly diagnosed T2DM, n = 50), and group 3 (long-standing diagnosed T2DM, n = 50). An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Subfatin (Metrnl), and the correlations of Metrnl level with anthropometric parameters, HOMA index, and biochemical measurements were assessed.

Results: There was no statistically significant difference between the gender (p = 0.468) and age (p = 0.067) characteristics of the three groups. The Metrnl (subfatin) levels of the participants were as follows: control group – 20.05 (1.56–103.78); newly diagnosed T2DM group – 2.62 (1.25–103.78); and long-standing diagnosed T2DM group – 2.01 (0.80–19.84) pg/mL. The Metrnl (subfatin) levels of the participants in the control group were higher than in the participants in the newly diagnosed T2DM and long-standing diagnosed T2DM groups (p < 0.001). Subfatin demonstrated a negative correlation with insulin and HOMA-IR in the control group and long-standing diagnosed T2DM group.

Conclusions: The subfatin level was found to be higher in the healthy control group than in both diabetic patient groups. Subfatin level showed negative correlation with both insulin level and HOMA index. There was a relationship between subfatin and insulin resistance. Low levels of subfatin in the diabetic patient groups may play a role in the pathogenesis of T2DM by increasing insulin resistance.

Article available in PDF format

View PDF Download PDF file

References

  1. Diagnosis, Classification and Screening in Glycemic Disorders. TEMD Guidelines for Diagnosis, Treatment and Follow-up of Diabetes Mellitus and Complications. 9th ed. Turkish Endocrinology and Metabolism Association 2017.
  2. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep. 2002; 4(2): 105–111.
  3. Li ZY, Zheng SL, Wang P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014; 20(4): 344–354.
  4. Jørgensen JR, Fransson A, Fjord-Larsen L, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. 2012; 233(1): 172–181.
  5. Zheng SL, Li ZY, Song J, et al. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016; 37(5): 571–579.
  6. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157(6): 1279–1291.
  7. Li ZY, Song J, Zheng SL, et al. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes. 2015; 64(12): 4011–4022.
  8. Ushach I, Burkhardt AM, Martinez C, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015; 156(2): 119–127.
  9. Dadmanesh M, Aghajani H, Fadaei R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018; 13(9): e0204180.
  10. Fadaei R, Dadmanesh M, Moradi N, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2018 [Epub ahead of print]: 1–6.
  11. Chung HS, Hwang SY, Choi JuH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018; 136: 100–107.
  12. Wang K, Li F, Wang C, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019; 25: 2337–2343.
  13. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep. 2002; 4(2): 105–111.
  14. Lee JuH, Kang YE, Kim JiM, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract. 2018; 135: 7–10.
  15. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018; 42(4): 919–922.
  16. Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017; 41(1): 112–119.